Market Place
Sourcing Support
Orchard Therapeutics Announces Reimbursement Agreement in Spain
28 Feb 2025 //
GLOBENEWSWIRE
Orchard Announces Data Presentations, Wins WORLDSymposium Award
03 Feb 2025 //
GLOBENEWSWIRE
Orchard Celebrates Global Progress In Newborn Screening For MLD
28 Jun 2024 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
07 May 2024 //
GLOBENEWSWIRE
Orchard`s Gaspar Named To Inaugural TIME100 Health List
03 May 2024 //
GLOBENEWSWIRE
Orchard Therapeutics Receives FDA Approval of Lenmeldy(atidarsagene autotemcel),
18 Mar 2024 //
GLOBENEWSWIRE
Orchard Announces Data in Programs Targeting CNS Disorders at ASGCT
19 May 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Presents Data from Research Programs at ASGCT
18 May 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Completes ADS Ratio Change
10 Mar 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
06 Mar 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results
06 Mar 2023 //
GLOBENEWSWIRE
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
03 Mar 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Proposed ADS Ratio Change
10 Feb 2023 //
GLOBENEWSWIRE
Orchard Announces Comprehensive Presence at 19th Annual WORLDSymposium
08 Feb 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Promising Early Neurocognitive OTL-201 MPS-IIIA
12 Dec 2022 //
GLOBENEWSWIRE
Swissmedic validates Orchard’s MAA for Libmeldy to treat early-onset
04 Dec 2022 //
PHARMABIZ
Orchard Announces Swissmedic Validation of the Mak Authorization for Libmeldy
01 Dec 2022 //
GLOBENEWSWIRE
Orchard Therapeutics Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Orchard Therapeutics to Webcast Conference Call of 3Q 2022 Financial Results
07 Nov 2022 //
GLOBENEWSWIRE
Orchard Announces First Neurocognitive Data from OTL-201 Study
03 Nov 2022 //
GLOBENEWSWIRE
Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress
10 Oct 2022 //
GLOBENEWSWIRE
Orchard Announces Multiple Presentations at 2022 SSIEM Annual Symposium
29 Aug 2022 //
GLOBENEWSWIRE
Oxford Biomedica initiates new project with Orchard Therapeutics
26 Jul 2022 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Presentations at ASGCT 2022
10 May 2022 //
GLOBENEWSWIRE
Orchard Tx to Webcast Conference Call of First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Orchard Tx Announces Reimbursement Agreement for MLD Patients in Italy
11 Apr 2022 //
GLOBENEWSWIRE
Orchard once again restructures, shedding gene therapy programs and staff
31 Mar 2022 //
BIOSPACE
Orchard Tx to Webcast Conference Call of Q4 & Fiscal Year 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
Orchard Tx to Present at Multiple Investor Conferences in March 2022
03 Mar 2022 //
GLOBENEWSWIRE
Orchard Therapeutics secures rare agreement on gene therapy coverage
07 Feb 2022 //
HEALTHCAREAFRICA
Orchard Therapeutics Announces Multiple Presentations at WORLDSymposium™ 2022
07 Feb 2022 //
GLOBENEWSWIRE
Orchard Tx Announces Historic Agreement Making Libmeldy Available by NHS England
03 Feb 2022 //
GLOBENEWSWIRE
Orchard`s Long-term Clinical Outcomes with Libmeldy published in The Lancet
21 Jan 2022 //
GLOBENEWSWIRE
Orchard Tx Announces Commercial & Regulatory Progress for Gene Therapy Programs
10 Jan 2022 //
GLOBENEWSWIRE
Orchard Therapeutics Announces New England Journal of Medicine Publication
18 Nov 2021 //
GLOBENEWSWIRE
Orchard Therapeutics Outlines Comprehensive Presence at the European Society
13 Oct 2021 //
GLOBENEWSWIRE
AffyImmune snags $30M for `tune and track` platform for CAR-T
08 Oct 2021 //
FIERCEBIOTECH
Orchard Outlines Differentiated Profile of Its HSC Gene Therapy Approach
14 Sep 2021 //
GLOBENEWSWIRE
Orchard picks Novartis cell and gene leader as next CTO
09 Sep 2021 //
FIERCEBIOTECH
Orchard Bolsters R&D and Technical Operations with New Executive Appointments
09 Sep 2021 //
GLOBENEWSWIRE
NICE ‘no’ for Orchard Therapeutics’ gene therapy Libmeldy
12 Jul 2021 //
PHARMA TIMES
NICE says no dice to Orchard`s pricey therapy for rare disease
09 Jul 2021 //
FIERCEPHARMA
Orchard Pharming team up to develop and commercialize HSC gene therapy
02 Jul 2021 //
PHARMABIZ
Orchard Therapeutics and Pharming Group Announce Collaboration
01 Jul 2021 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Regulatory & Clinical Updates
29 Jun 2021 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meetin
28 Apr 2021 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Interim Data for OTL-203 Showing
10 Feb 2021 //
GLOBENEWSWIRE
Orchard Announces Interim Data for OTL-203 Showing Positive Clinical Results
09 Feb 2021 //
GLOBENEWSWIRE
Orchard Therapeutics Announces $150 Million Strategic Financing
05 Feb 2021 //
GLOBESNEWSWIRE
Orchard Therapeutics Outlines Comprehensive Presence at 2021 WORLDSymposium™
28 Jan 2021 //
PRESS RELEASE
Orchard Secures Partnerships to Broaden Access to LibmeldyTM
19 Jan 2021 //
GLOBENEWSWIRE
Orchard Announces OTL-200 Granted (RMAT) Designation by FDA
14 Jan 2021 //
GLOBENEWSWIRE
Orchard Announces 2021 Corporate Priorities Supporting the Build-out
11 Jan 2021 //
GLOBENEWSWIRE
AGC Biologics Confirms Cell and Gene Therapy Commercial Expertise as Mfg
04 Jan 2021 //
GONZAGABULLETIN
Orchard Therapeutics Reports OTL-201 Initial Clinical Data Sanfilippo Syndrome
08 Dec 2020 //
GLOBENEWSWIRE
Orchard Unveils Details on New HSC Gene Therapy Research Programs
12 Nov 2020 //
GLOBENEWSWIRE
Orchard Announces New OTL-201 Data in Sanfilippo Syndrome TY A (MPS-IIIA)
05 Nov 2020 //
GLOBENEWSWIRE
Orchard Reviews Recent Portfolio Progress and Reports 3Q 2020
03 Nov 2020 //
GLOBENEWSWIRE
Orchard Statement on Strimvelis®, a Gammaretroviral Vector-Based Gene Therapy
02 Nov 2020 //
PRESS RELEASE
Orchard halts dosing of EMA-approved Strimvelis after patient develops leukemia
02 Nov 2020 //
ENDPTS
